ArticleBMC gastroenterology2025
Association between the ApoB/ApoA1 ratio and both the severity and mortality of metabolic dysfunction-associated fatty liver disease.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe association between the ApoB/ApoA1 ratio and the severity and prognosis of hepatic steatosis in metabolic dysfunction-associated fatty liver disease (MAFLD) is unclear. This study aims to elucidate the association between the ApoB/ApoA1 ratio and the severity of hepatic steatosis in this population, as well as its connections to all-cause and cause-specific mortality.
methodsData for this research were sourced from Beijing, China, and incorporated from the Third National Health and Nutrition Examination Survey (NHANES III) and the National Death Index (NDI) in the United States. Multivariate logistic regression analysis was employed to examine the relationship between the ApoB/ApoA1 ratio and MAFLD, as well as its severity. Additionally, multivariable Cox regression and restricted cubic spline (RCS) regression models were utilized to evaluate the association between the ApoB/ApoA1 ratio and long-term all-cause and cause-specific mortality among MAFLD patients, including subgroup analyses.
resultsAfter adjusted for confounders, a significant correlation was identified between the ApoB/ApoA1 ratio and both the presence of MAFLD and its severity (all P < 0.05). In mortality analyses, the multivariate Cox regression, also adjusted for confounders, indicated that the ApoB/ApoA1 ratio was significantly linked to overall mortality (HR = 1.52, 95%CI: 1.17–1.98, P = 0.002), cardiovascular-related mortality (HR = 1.76, 95%CI: 1.12–2.77, P = 0.014), and diabetes-related mortality (HR = 2.20, 95%CI: 1.21–4.01, P = 0.010) among MAFLD patients. The RCS curves displayed a linear relationship between the ApoB/ApoA1 ratio and both all-cause and cause-specific mortality (all P for non-linear > 0.05) within the MAFLD cohort. Furthermore, insulin resistance-related indicators mediated the association between the ApoB/ApoA1 ratio and all-cause mortality.
conclusionThe findings of this study suggest that the ApoB/ApoA1 ratio is a significant predictor for assessing the severity of MAFLD and hepatic steatosis. Furthermore, insulin resistance-related indicators mediated the association between the ApoB/ApoA1 ratio and all-cause mortality.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.